In vivo synergism of free miltefosine or in alginate-based nanocarrier combined with voriconazole on aspergillosis

• Published in: Future microbiology Vol. 16; no. 15; pp. 1153 - 1160
• Main Authors: Barreto, Thayná L, Lopes, Luciana B, Melo, Analy Sa, Ishida, Kelly
• Format: Journal Article
• Language: English
• Published: England 01-10-2021
• Subjects: Alginates; Antifungal Agents - pharmacology; Aspergillus flavus - drug effects; Aspergillus fumigatus - drug effects; Drug Carriers; Drug Synergism; Nanoparticles; Phosphorylcholine - analogs & derivatives; Phosphorylcholine - pharmacology; Voriconazole - pharmacology; synergism; Aspergillus flavus; Galleria mellonella; Aspergillus fumigatus; alginate nanoparticles
• ISSN: 1746-0913; 1746-0921
• DOI: 10.2217/fmb-2021-0056

To evaluate the activity of miltefosine (MFS), in its free form or loaded-alginate nanoparticles (MFS-AN), alone or combined with voriconazole (VRC) on
and
.
A broth microdilution assay was used for the susceptibility testing of
isolates, and the antifungal efficacy was assessed using the aspergillosis model in
larvae.
The
synergistic effect of MFS with VRC was observed only against
, whereas both combined therapies (MFS + VRC and MFS-AN + VRC) showed synergism in reducing the larval mortality rate and fungal burden in the larvae infected by
and
.
MFS and MFS-AN combined with VRC may be an important strategy for improving antifungal therapy against aspergillosis.